MDGL EBITDA Growth
Madrigal Pharmaceuticals Inc · EBITDA Growth
MDGL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-9.50%period ending
MDGL TTM EBITDA YoY % (22.07% → -9.50%)
Year-over-year change
High-resolution chart · PNG
MDGL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -9.4953% | |
| 25.2712% | |
| 41.2453% | |
| 46.2575% | |
| 46.0869% | |
| 12.4191% | |
| -24.8988% | |
| -49.4189% | |
| -54.1915% | |
| -39.4702% | |
| -23.8802% | |
| -24.0117% | |
| -25.9838% | |
| -24.9676% | |
| -20.2771% | |
| -14.5219% | |
| -9.5292% | |
| -11.407% | |
| -17.2995% | |
| -34.0604% | |
| -66.7908% | |
| -103.1522% | |
| -139.6304% | |
| -161.4748% | |
| -155.0612% | |
| -162.8253% | |
| -163.0292% | |
| -127.9056% | |
| -85.1911% | |
| -31.8502% | |
| -5.2709% | |
| 2.6201% | |
| -22.2119% | |
| -70.2789% | |
| -136.425% | |
| -95.0561% | |
| -67.3584% | |
| 40.7238% | |
| 74.0221% | |
| 74.0284% | |
| 81.618% | |
| 61.4285% | |
| 39.2409% | |
| 30.8% | |
| 12.0065% | |
| 9.9549% | |
| 4.3254% | |
| -6.7921% | |
| -20.4786% | |
| -35.7405% | |
| -44.5825% | |
| -54.7286% | |
| -47.9226% | |
| -38.1991% | |
| -36.9246% | |
| -25.3829% | |
| -25.746% | |
| -30.0063% | |
| -25.7486% | |
| -25.0358% | |
| -142.1728% | |
| -138.6173% | |
| -142.4338% | |
| -152.6499% | |
| 217.6892% | |
| 200.456% | |
| 190.5573% | |
| 178.3554% | |
| -14.3972% | |
| -47.0575% | |
| -44.7426% | |
| -36.4128% | |
| -17.6733% | |
| -11.2614% | |
| -11.0456% | |
| 0.5791% | |
| 17.2793% | |
| 30.9039% | |
| 34.879% | |
| 22.066% |